Fig. 2: Preformed BAK/MCL1 complexes predict cancer cell sensitivity to paclitaxel and S63845.
From: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
a–f After the cell lines were treated with paclitaxel (a), S63845 (b), vincristine (c), navitoclax (d), etoposide (e), or carboplatin (f) for 48 h, the percentages of sub-G1 cells were assessed by flow cytometry (n = 3–5 independent experiments, means ± S.D.). Cells with BAK status classified as BAK/MCL1, BAK/BCLXL, BAK/MCL1 + BAK/BCLXL, and none are indicated with orange, blue, red, and green, respectively. The numbers before each cell line in the Inset will be used to represent the cell lines in Figs. 2,  4,  5, and Supplementary Figs. 4 and 7. g–i The correlations of BAK/MCL1 complexes and cell death induced by paclitaxel 8 nM (g), S63845 4 μM (h), and carboplatin 75 μM (i) were analyzed using Spearman rank correlation, respectively. j–l The correlations of BAK/BCLXL complexes and cell death induced by paclitaxel 8 nM (j), S63845 4 μM (k), and carboplatin 75 μM (l) were analyzed using Spearman rank correlation, respectively. m, n Cell lines were grouped into three different groups according to the percentage of BAK bound to MCL1 (BAK/MCL1), and the apoptosis induced by paclitaxel 8 nM (m), or S63845 4 μM (n) was indicated for each cell line.
